Bringing Biologics Medical Innovation to International Markets

 

About Us

KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals.   Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines.  The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion)

 

Business Lines

Screen Shot 2021-12-26 at 10.31.32 AM.png

Geographic Focus

Screen Shot 2022-01-09 at 9.32.00 AM.png

Business Model and Value Proposition

Screen Shot 2022-01-09 at 4.40.02 PM.png

The Opportunity

Screen Shot 2022-01-09 at 10.59.54 AM.png
Laboratory
 

Management Team

Screen Shot 2022-01-09 at 11.53.43 AM.png

Board Members and Current Investors

Screen Shot 2022-01-09 at 11.56.37 AM.png
 
Lab Experiments

Pipeline

IMG_8422.JPG
 
Screen Shot 2022-01-09 at 4.21.07 PM.png

Platforms of Interest

Screen Shot 2022-01-09 at 11.57.05 AM.png

Manufacturing

 
Screen Shot 2022-01-09 at 12.13.51 PM.png

Contract Manufacturing Clientele

Screen Shot 2022-01-09 at 4.08.55 PM.png

GET IN TOUCH

Kalbe building 3rd floor. Jl. Letjend Suprapto Kav 4, Jakarta 10510, Indonesia

(6221) 42873888

Thanks for submitting!